Based on the results of the current work and existing evidence from previous clinical and experimental research, we propose that inhibition of MC-tryptase and MC-tryptase-dependent activation of PAR-2 may present novel targeted therapeutics for the management of neurological dysfunction, particularly cognitive impairment after CA. Here, F2RL1 is linked to Cognitive impairment.